Improved Outcome of Relapsed/Refractory B-Cell Lymphomas Treated in Phase I Trials with T-Cell Engaging Bispecific Antibodies: A Single Center Experience

Background.Phase I trials usually enroll patients (pts) refractory to standard treatments in order to evaluate the toxicity, pharmacokinetic and preliminary efficacy of new therapeutic agents. However, in the last decade, the emergence of targeted and immune therapies has rapidly expanded the scope and eligibility of phase I trials which currently include also the efficacy assessment. This is particularly evident in B-cell non-Hodgkin lymphomas (NHL), were several treatments proved substantial efficacy in the relapsed/refractory (R/R) setting. Specifically, T-cell based immunotherapy i.e. CART cells and T-cell engaging bispecific antibodies (BSA) showed practice changing results. Aim of this study was to compare the outcome of pts enrolled in phase I trials treated with BSA-based treatment versus all the other treatment modality, with the exclusion of CART cells therapy.